Galapagos achieves multiple milestones in rheumatoid arthritis alliance
Galapagos NV announced achievement of multiple milestones under its alliance agreement in rheumatoid arthritis. The milestones trigger a cash payment of €10.2 million to Galapagos.
In October 2007, Galapagos announced an alliance agreement with Janssen Pharmaceutica NV providing Janssen with option rights to acquire worldwide, commercial licenses to novel small molecules from up to 12 of Galapagos' internal programs involving rheumatoid arthritis therapeutic targets. The milestones announced today are the result of several of these programs reaching the next phase of medicinal chemistry optimization.
"We are pleased that the molecules derived under the rheumatoid arthritis alliance have met the agreed upon criteria," said Onno van de Stolpe, CEO of Galapagos. "Galapagos continues to deliver high quality research and remains on course for achieving its goals for the year."
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.